ADORA2A and neoplasm: • A2AR and A2BR heterodimers diminish ligand affinity for A2AR.• Endosomal GPCR signaling.• ENT1 driven Ado entry to immune cells.• Spliced variants of A2AR in tumor cells worsen the disease.